Literature DB >> 28088464

Microparticles: Inflammatory and haemostatic biomarkers in Polycystic Ovary Syndrome.

L M L Carvalho1, C N Ferreira2, M O Sóter3, M F Sales1, K F Rodrigues1, S R Martins3, A L Candido4, F M Reis4, I F O Silva3, F M F Campos3, K B Gomes5.   

Abstract

Polycystic Ovary Syndrome (PCOS) is associated with a chronic low-grade inflammation and predisposition to hemostatic and atherosclerotic complications. This case-control study evaluated the microparticles (MPs) profile in patients with the PCOS and related these MPs to clinical and biochemical parameters. MPs derived from platelets (PMPs), leuckocytes (LMPs) and endothelial cells (EMPs) were evaluated, as well as MPs expressing tissue factor (TFMPs), by flow cytometry, comparing women with PCOS (n = 50) and a healthy control group (n = 50). PCOS women presented increased total MPs, PMPs, LMPs and EMPs levels when compared to control group (all p < 0.05). TFMPs was similar between the groups (p = 0.379). In conclusion, these MPs populations could be useful biomarkers for association with thrombosis and cardiovascular disease in PCOS women.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endothelial cells; Leukocytes; Microparticles; Platelets; Polycystic Ovary Syndrome; Tissue factor

Mesh：

Substances：

Year:  2017        PMID： 28088464     DOI： 10.1016/j.mce.2017.01.017

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN： 0303-7207            Impact factor:   4.102


  7 in total

1.  Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome.

Authors:  Laura M L Carvalho; Cláudia N Ferreira; Daisy K D de Oliveira; Kathryna F Rodrigues; Rita C F Duarte; Márcia F A Teixeira; Luana B Xavier; Ana Lúcia Candido; Fernando M Reis; Ieda F O Silva; Fernanda M F Campos; Karina B Gomes
Journal:  J Assist Reprod Genet       Date:  2017-09-13       Impact factor: 3.412

2.  Polycystic ovary syndrome: clinical and laboratory variables related to new phenotypes using machine-learning models.

Authors:  A A Veloso; K B Gomes; I S Silva; C N Ferreira; L B X Costa; M O Sóter; L M L Carvalho; J de C Albuquerque; M F Sales; A L Candido; F M Reis
Journal:  J Endocrinol Invest       Date:  2021-09-15       Impact factor: 4.256

3.  Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: A systematic review and meta-analysis.

Authors:  Chan Hee Kim; Seung Joo Chon; Seon Heui Lee
Journal:  Sci Rep       Date:  2020-05-08       Impact factor: 4.379

4.  The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome.

Authors:  Zeeshan Javed; Maria Papageorgiou; Leigh A Madden; Alan S Rigby; Eric S Kilpatrick; Stephen L Atkin; Thozhukat Sathyapalan
Journal:  Endocr Connect       Date:  2020-06       Impact factor: 3.335

5.  The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects.

Authors:  Ahmed Al-Qaissi; Saeed Alqarni; Zeeshan Javed; Stephen L Atkin; Thozhukat Sathyapalan; Rebecca V Vince; Leigh A Madden
Journal:  Endocrine       Date:  2019-08-27       Impact factor: 3.633

6.  Assessing C reactive protein/albumin ratio as a new biomarker for polycystic ovary syndrome: a case-control study of women from Bahraini medical clinics.

Authors:  Shirin Kalyan; Azita Goshtesabi; Sameh Sarray; Angela Joannou; Wassim Y Almawi
Journal:  BMJ Open       Date:  2018-10-27       Impact factor: 2.692

7.  Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules.

Authors:  Praveenkumar Devarbhavi; Lata Telang; Basavaraj Vastrad; Anandkumar Tengli; Chanabasayya Vastrad; Iranna Kotturshetti
Journal:  Reprod Biol Endocrinol       Date:  2021-02-23       Impact factor: 5.211
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.